港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

530.707

-2.141-0.40%

漲家數：8

跌家數：24

平家數：1

市盈率：- -

高：543.539

開：532.796

低：528.924

收：532.848

成交量：6,467.71萬

成交額：15.64億

市值：3,389.57億

流通市值：3,020.22億

資料載入中...

總覽新聞資訊

港股異動 | 科濟藥業-B(02171.HK)再升逾4% 旗下通用型CAR-T接連獲批愷力美納入百萬醫療險

創新藥「多點開花」「癌症慢病化」深刻影響醫藥產業

港股異動 | 微創心通-B(02160)漲近5% 預計上半年虧損不高於2500萬美元全球心律管理業務持續穩定增長

港股異動 | 微創心通-B(02160.HK)漲近5% 預計上半年虧損不高於2500萬美元全球心律管理業務持續穩定增長

再鼎醫藥午前升逾5% 公司自主研發資產正逐步進入臨床價值驗證階段

出海提速+中報兑現+AI賦能，創新藥板塊景氣修復延續！T+0恒生創新藥ETF華泰柏瑞（520500）年內份額增長77%

醫藥調研熱度超越半導體！創新藥回調，華寶基金港股通創新藥ETF失守半年線！CXO韌性十足，藥明系逆市飄紅

港股異動 | 再鼎醫藥(09688.HK)再升逾5% 核心管線迎來密集催化創新將成下一階段增長核心動力

科濟藥業－Ｂ(02171)股價上升5.023%，現價港幣$15.89

阿斯达克财经

創新藥人氣股，2分鐘直線漲停

國家藥監局批准2款創新藥上市

南方财经网

港股開盤 | 恒指低開0.6% 黃金股走強再鼎醫藥(09688)升逾8%

港股開盤｜港股開盤持平；醫藥股走強；再鼎醫藥升逾8%

指數震盪分化觀望情緒升温，聚焦醫藥與算力鏈內部的輪動機會

再鼎醫藥(09688)出現大手賣出77.63萬股，成交價$20.02，涉資1.554千萬

阿斯达克财经

微創心通-B：預計上半年淨虧損不超2500萬美元

住友製藥株式會社：沽空機構哥譚市研究（Gotham City Research，簡稱GCR）於2026年8月3日發布

盈利走強產品放量出海破局——從業績預告看創新藥行業發展

经济参考报

虧損持續、現金緊張、對賭高懸普祺醫藥再次向港交所遞交IPO申請

八月新基供給走弱醫藥板塊獲逆向佈局

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":530.7069,"timestamp":1786516560868,"preClose":532.84753,"halted":0,"volume":64677073,"delay":0,"changeRate":-0.004017,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-2.140625,"latestTime":"08-12 14:36:01","open":532.796,"high":543.53937,"low":528.924,"amount":1564481372,"amplitude":0.027429,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1786522200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1786498200000,1786507200000],[1786510800000,1786521600000]],"pbRate":4.320612,"peRate":-81.172646,"turnoverRate":0.002348,"increases":8,"decrements":24,"flats":1,"marketCap":338957027440,"floatMarketCap":302021806224},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":543.53937,"amplitude":0.027429,"preClose":532.84753,"low":528.924,"pbRate":"4.320612","latestPrice":530.7069,"volume":64677073,"delay":0,"open":532.796,"prevYearClose":556.26263,"prevWeekClose":516.343,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":485.719,"twentyDayClose":525.18,"sixtyDayClose":579.587,"secType":"PLATE","market":"HK","turnoverRate":0.002348,"peRate":-81.172646,"marketCap":338957027440,"floatMarketCap":302021806224,"timestamp":1786516560868,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":8,"down":24,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658926656","title":"港股異動 | 科濟藥業-B(02171.HK)再升逾4% 旗下通用型CAR-T接連獲批 愷力美納入百萬醫療險","url":"https://stock-news.laohu8.com/highlight/detail?id=2658926656","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658926656?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 13:42","pubTimestamp":1786513321,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02171","BK1574","BK1587","BK1161","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692341","title":"創新藥「多點開花」 「癌症慢病化」深刻影響醫藥產業","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692341","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658692341?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 12:14","pubTimestamp":1786508074,"startTime":"0","endTime":"0","summary":"国家药监局最新数据显示，今年上半年我国批准38个1类创新药上市，其中11个新靶点、新机制药物全部为国产自主研发。在这11个具备全球首创潜力的创新药中，抗肿瘤药物占4个。随着更多抗肿瘤新药获批上市，靶向、免疫、细胞治疗等新疗法不断取得突破，越来越多癌症患者的生存周期从“按周、按月计算”拉长至“按年甚至十年计算”。医学技术进步推进癌症慢病化，也对医药产业发展产生显著影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608123839000216.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608123839000216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","BK1161","06978","159992","BK1574","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658923868","title":"港股異動 | 微創心通-B(02160)漲近5% 預計上半年虧損不高於2500萬美元 全球心律管理業務持續穩定增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2658923868","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658923868?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 11:55","pubTimestamp":1786506906,"startTime":"0","endTime":"0","summary":"消息面上，微创心通公告，由于集团于2025年12月19日完成收购心律管理业务，心律管理业务于截至2026年6月30日止六个月首次全部合并入本集团财务报表。根据目前可得最新资料的评估，预期报告期取得收入不低于1.53亿美元，净亏损不高于2500万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4588","BK1239","BK1100","BK1574","BK4585","HART","02160","VXUS","BK1225","KCAI","02918"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658238509","title":"港股異動 | 微創心通-B(02160.HK)漲近5% 預計上半年虧損不高於2500萬美元 全球心律管理業務持續穩定增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2658238509","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658238509?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 11:55","pubTimestamp":1786506906,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","BK1225","02918","BK1574","02160","BK1583","BK1239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658081928","title":"再鼎醫藥午前升逾5% 公司自主研發資產正逐步進入臨床價值驗證階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2658081928","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658081928?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 11:45","pubTimestamp":1786506300,"startTime":"0","endTime":"0","summary":"模拟交易客户端再鼎医药早盘一度涨超11%，绩后股价已累涨超三成。截至发稿，股价上涨5.13%，现报19.48港元，成交额3.59亿港元。再鼎医药今年二季度实现总收入为1.063亿美元，产品收入净额为1.058亿美元，环比增长11%，得益于则乐的稳定表现以及艾加莫德的销量持续增长。中信建投指出，公司自主研发资产正逐步进入临床价值验证阶段，核心自研管线有望于年内迎来密集数据读出及关键研发进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-12/doc-inimzqcr3698280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK1574","BK1588","BK1161","09688","BK4526","BK4531","BK4588","ZLAB","BK4548","LU2488822045.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658447928","title":"出海提速+中報兑現+AI賦能，創新藥板塊景氣修復延續！T+0恒生創新藥ETF華泰柏瑞（520500）年內份額增長77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658447928","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658447928?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 11:33","pubTimestamp":1786505580,"startTime":"0","endTime":"0","summary":"下半年以来，创新药板块的修复行情持续推进。作为当前A股市场仅有的跟踪恒生创新药指数的ETF，恒生创新药ETF华泰柏瑞今年以来合计“吸金”14.45亿元，助推基金份额与规模分别攀升至22.10亿份、32.30亿元，较年初分别增长77%、67%，流动性优势较突出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-08-12/doc-inimzqcv4064339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ARTY","QTOC","LNGR","AGIX","06978","BK1161","CHAT","159992","BK1574","AIPO","520500","MEDX","IBBQ","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658288069","title":"醫藥調研熱度超越半導體！創新藥回調，華寶基金港股通創新藥ETF失守半年線！CXO韌性十足，藥明系逆市飄紅","url":"https://stock-news.laohu8.com/highlight/detail?id=2658288069","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658288069?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 11:02","pubTimestamp":1786503720,"startTime":"0","endTime":"0","summary":"业绩兑现叠加AI制药概念加持，CXO韧性十足，药明生物、药明康德、药明合联逆市飘红，金斯瑞生物科技续涨逾1%。港股通创新药龙头股批量飘绿，百济神州跌2%止步6连阳，翰森制药跌逾3%；再鼎医药延续涨势，股价创年内新高。100%创新药研发标的——港股通创新药ETF华宝冲高回落，现跌1%再失半年线。8月以来，创新药及产业链利好密集，“吃药”行情持续上演。同期医药生物行业的市场关注度大幅攀升。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-12/doc-inimzqcp6895872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PSI","VGT","BK4588","CXO","NBDS","BK1515","SOXY","USD","SMH","TECY","MEDX","EIS","CHPY","SSG","SMHU","SOXL","BK4535","LNGR","SMHX","IBBQ","CHPS","159938","SOXQ","FTXL","159316","FWD","BK1574","WX","SOXX","XSD","BK1161","BK4585","MQQQ","FLHK","09939","159992","06978","159582","TEKX","CWC","SOXS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658407879","title":"港股異動 | 再鼎醫藥(09688.HK)再升逾5% 核心管線迎來密集催化 創新將成下一階段增長核心動力","url":"https://stock-news.laohu8.com/highlight/detail?id=2658407879","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658407879?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 10:53","pubTimestamp":1786503210,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","BK1588","LU2488822045.USD","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658928372","title":"科濟藥業－Ｂ(02171)股價上升5.023%，現價港幣$15.89","url":"https://stock-news.laohu8.com/highlight/detail?id=2658928372","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658928372?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 10:53","pubTimestamp":1786503180,"startTime":"0","endTime":"0","summary":"[上升股]科济药业－Ｂ(02171) 股价在上午10:52比前收市价上升5.023%，现股价为港币$15.89。至目前为止，今日最高价为$15.89，而最低价为$15.18。总成交量为102.6万股，总成交金额为港币$1.609千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608121605/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608121605/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02171","BK1587","BK1585","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658409069","title":"創新藥人氣股，2分鐘直線漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2658409069","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658409069?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 10:21","pubTimestamp":1786501260,"startTime":"0","endTime":"0","summary":"此前在8月10日，百花医药发布股票交易异常波动公告称，公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归母净利润664.27万元，同比下降67.94%。公司股价短期内波动较大，公司股票目前已累积较大二级市场交易风险，未来存在快速下跌的风险。创新药板块中，誉衡药业涨超9%，万邦医药涨超8%，泓博医药、昆药集团、陇神戎发、美迪西跟涨。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-08-12/doc-inimzivt3775229.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-08-12/doc-inimzivt3775229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","LNGR","IBBQ","BK1574","06978","159992","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658866940","title":"國家藥監局批准2款創新藥上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2658866940","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658866940?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 09:51","pubTimestamp":1786499460,"startTime":"0","endTime":"0","summary":"南方财经8月12日电，近日，国家药品监督管理局通过优先审评审批程序，附条件批准药捷安康（南京）科技股份有限公司申报的1类创新药替恩戈替尼片（商品名称：捷恩泰）上市，该药用于既往接受过系统性治疗和FGFR抑制剂治疗，且具有成纤维细胞生长因子受体（FGFR）2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者的治疗。该药品上市为患者提供了新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608123838902271.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608123838902271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","LNGR","BK1161","MEDX","IBBQ","06978","IPOS","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658947545","title":"港股開盤 | 恒指低開0.6% 黃金股走強 再鼎醫藥(09688)升逾8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658947545","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658947545?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 09:29","pubTimestamp":1786498159,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月12日，恒生指数低开0.6%，报25498.39点；恒生科技指数跌0.8%，报4785.75点；国企指数跌0.57%，报8479.60点。大市盘前成交21.70亿港元。黄金股走强，紫金黄金国际涨超2%，中国黄金国际涨超2%，灵宝黄金涨超2%，老铺黄金涨近2%，山东黄金涨超1%。医药股走强，再鼎医药涨超8%，药明合联涨超1%。受再鼎医药隔夜美股涨超10%带动。受隔夜美股三大指数全线收跌、中概股金龙指数跌2.94%拖累，港股今日低开。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1588","BK1574","LU2488822045.USD","ZLAB","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168242546","title":"港股開盤｜港股開盤持平；醫藥股走強；再鼎醫藥升逾8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168242546","media":"港股开盘","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168242546?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 09:21","pubTimestamp":1786497715,"startTime":"0","endTime":"0","summary":"盘面上，生物医药、资源金属及AI概念活跃，带动个股分化上行；在线娱乐、教育等消费服务类个股则出现回吐，市场风格短线偏向防御与结构性轮动。大型科技股延续弱势，多数回调逾0.5%，仅理想汽车小幅飘红；阿里、腾讯、京东等均低开，或受隔夜美股科技股走软及机构获利了结影响。盘面亮点集中在生物医药与资源股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK4531","ZLAB","09688","VXUS","BK1515","BK4548","BK1161","BK1588","BK4526","BK4588","KCAI","BK1574","09939","BK4585","159938","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658478149","title":"指數震盪分化觀望情緒升温，聚焦醫藥與算力鏈內部的輪動機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2658478149","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658478149?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 09:20","pubTimestamp":1786497609,"startTime":"0","endTime":"0","summary":"　　昨日市场全天震荡分化，三大指数涨跌不一，创业板指小幅收红。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/zldongxiang/20260812/32332314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK1574","159938","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658947954","title":"再鼎醫藥(09688)出現大手賣出77.63萬股，成交價$20.02，涉資1.554千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2658947954","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658947954?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 09:20","pubTimestamp":1786497600,"startTime":"0","endTime":"0","summary":"[大手成交]再鼎医药(09688)在上午09:20出现大手卖出，成交量为77.63万，成交价为港币$20.02，涉资1.554千万。至目前为止，股价升8.041%，今日最高价为$20.02，而最低价为$20.02，总成交量为77.63万股，总成交金额港币$1.554千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT26081238/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT26081238/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1588","BK1574","LU2488822045.USD","BK1161","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658194263","title":"微創心通-B：預計上半年淨虧損不超2500萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658194263","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658194263?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 08:40","pubTimestamp":1786495200,"startTime":"0","endTime":"0","summary":"8月11日，微创心通-B（02160）发布公告，由于公司于2025年12月19日完成收购心律管理业务，该业务于2026年上半年首次全部合并入公司财务报表。根据初步审阅，公司预计2026年上半年录得收入不低于1.53亿美元，净亏损不高于2500万美元。在报告期内，公司全球心律管理业务持续稳定增长，其中中国市场起搏器植入量录得双位数增幅。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608123838567556.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608123838567556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1225","02160","BK1583","BK1239","BK1574","02918","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658412429","title":"住友製藥株式會社： 沽空機構哥譚市研究（Gotham City Research，簡稱GCR） 於2026年8月3日發布","url":"https://stock-news.laohu8.com/highlight/detail?id=2658412429","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658412429?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 07:54","pubTimestamp":1786492497,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658691050","title":"盈利走強 產品放量 出海破局——從業績預告看創新藥行業發展","url":"https://stock-news.laohu8.com/highlight/detail?id=2658691050","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658691050?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 02:44","pubTimestamp":1786473854,"startTime":"0","endTime":"0","summary":"创新药板块近期持续走强。截至8月11日收盘，万邦医药涨20%，报70.39元/股，年内累计涨幅高达149%；百花医药走出6连板，收盘报12.75元/股，近5日涨幅60.98%；振东制药大涨14.26%，亚泰集团、甘李药业、哈药股份同步封板，板块做多情绪持续升温。二级市场热度涌动的背后，是创新药产业基本面迎来实质性改善。2026年上半年，国内创新药行业迎来业绩兑现窗口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608123838283832.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608123838283832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","IBBQ","06978","BK1574","159992","MEDX","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658594137","title":"虧損持續、現金緊張、對賭高懸普祺醫藥再次向港交所遞交IPO申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2658594137","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658594137?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 02:36","pubTimestamp":1786473360,"startTime":"0","endTime":"0","summary":"近日，北京普祺医药科技股份有限公司再次向港交所递交上市申请。在此前港股申请失效后，普祺医药重启IPO闯关。若本次IPO融资未能顺利完成，公司持续现金消耗或将引发经营危机。对赌契约高悬招股书显示，根据相关投资协议约定，公司控股股东之一也是普祺医药的创始人、董事长兼总经理李雨亮，向多名机构投资者授予多项特殊股东权利，主要包括反摊薄权与赎回权。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-12/doc-inimysxx7185762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS","BK1515","REDS","BK4127","BK1574","KCE","159938","09939","BK1161","HEXmain","FRHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658413249","title":"八月新基供給走弱 醫藥板塊獲逆向佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2658413249","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658413249?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 02:36","pubTimestamp":1786473360,"startTime":"0","endTime":"0","summary":"从行业特征来看，多家公募以行业主题发起式基金对细分赛道进行快速布局，其中，调整充分、估值处于低位的医药板块获得重点关注。公募机构借助发起式基金的低门槛优势，加速布局前期调整充分、估值回归合理区间的赛道，其中医药板块因调整时间较长、基本面韧性突出，已成为逆向投资的重点方向。截至目前，多只创新药ETF自年内低点反弹逾20%，合计吸金超百亿元；此外，还有部分医药主题主动权益基金最高涨幅超30%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-12/doc-inimysyf4300731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159938","BK1515","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":1,"totalSize":328,"code":"91000000","status":"200"}]}}